Needham analyst Ami Fadia maintains $Jazz Pharmaceuticals (JAZZ.US)$ with a buy rating, and maintains the target price at $207.
According to TipRanks data, the analyst has a success rate of 52.1% and a total average return of 7.4% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Jazz Pharmaceuticals (JAZZ.US)$'s main analysts recently are as follows:
Jazz Pharmaceuticals has reported third-quarter revenue that aligned with expectations, alongside a significant non-GAAP net income surplus, even though outcomes were momentarily affected by variables impacting the Rylaze brand. Overall, the third-quarter results were deemed 'solid.' It's believed that Jazz is positioned enticingly, with a valuation reflecting 'highly depressed multiples,' while still promising mid-single digit revenue growth and high-single digit profit growth rates on an annual compound basis.
Jazz Pharmaceuticals' Q3 revenue outperformance was propelled by robust expansion in its principal growth contributors, Xywav and Epidiolex. Conversely, Rylaze experienced a temporary setback due to modifications in the treatment protocol.
The firm noted that Jazz Pharmaceuticals' total Q3 revenue exceeded expectations, aided by the performance of Xywav, Epidiolex, Defitelio, and Zepzelca.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
